European Pharmaceutical Review

DECEMBER 20, 2023

1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. However, it is clear that changes are likely to have meaningful impacts for biopharma players if adopted.

Biopharma 98

Biopharma Pharmaceutical Medicine Manufacturing 98

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 is to acquire the 2015-established Amryt Pharma Plc. on 6 th January.

Pharma 85

Pharma Biopharma Management Medicine 85

European Pharmaceutical Review

DECEMBER 19, 2022

1 However, as most biosimilars are developed by means of a complex biotechnological process in living organisms, this inevitably leads to differences between the biosimilar and the reference product. Marie Manley leads Sidley’s Life Sciences team in London and is a distinguished thought leader and adviser on EU and UK regulatory law.

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

AUGUST 28, 2024

2: Patient flows for Humira versus generic competitors in France post-LOE Source: Clarivate Patient Data Intelligence “What we’re seeing here is the resilience of complex blockbuster biologics,” said Nicole Parisi, Clarivate Lead Business Analyst. In the U.S.,

Prescription 59

Prescription Marketing Patients Physicians 59

PM360

SEPTEMBER 28, 2022

Chrys Kokino has been involved in the biosimilars market prior to the first biosimilar being approved in Europe in 2006. Now, as the President of Accord BioPharma , the U.S. he is responsible for leading the commercialization efforts of specialty products which includes a broad portfolio of biosimilars.

Competition 98

Competition Marketing Manufacturing Biopharma 98

pharmaphorum

AUGUST 4, 2022

This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. For instance, in pharmaceutical manufacturing, mistakes in training can lead to contamination or waste, which can cause businesses unnecessary headaches.

Recruitment 92

Recruitment Pharma Training Pharmaceutical manufacturing 92

Clarivate

NOVEMBER 10, 2022

The evidence standards that a COA must meet to support key clinical trial endpoints have become increasingly stringent in recent decades, following the introduction of the United States Food and Drug Administration (FDA) Patient Reported Outcomes (PRO) draft guidance in 2006, followed by the full guidance in 2009.

Patients 52

Patients Food and Drug Administration FDA Safety 52